1. Home
  2. PCRX vs RYI Comparison

PCRX vs RYI Comparison

Compare PCRX & RYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • RYI
  • Stock Information
  • Founded
  • PCRX 2006
  • RYI 1842
  • Country
  • PCRX United States
  • RYI United States
  • Employees
  • PCRX N/A
  • RYI N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • RYI Metal Fabrications
  • Sector
  • PCRX Health Care
  • RYI Industrials
  • Exchange
  • PCRX Nasdaq
  • RYI Nasdaq
  • Market Cap
  • PCRX 1.2B
  • RYI 699.3M
  • IPO Year
  • PCRX 2011
  • RYI N/A
  • Fundamental
  • Price
  • PCRX $23.31
  • RYI $23.30
  • Analyst Decision
  • PCRX Buy
  • RYI Hold
  • Analyst Count
  • PCRX 8
  • RYI 1
  • Target Price
  • PCRX $28.38
  • RYI $25.00
  • AVG Volume (30 Days)
  • PCRX 537.5K
  • RYI 244.7K
  • Earning Date
  • PCRX 07-29-2025
  • RYI 07-29-2025
  • Dividend Yield
  • PCRX N/A
  • RYI 3.21%
  • EPS Growth
  • PCRX N/A
  • RYI N/A
  • EPS
  • PCRX N/A
  • RYI N/A
  • Revenue
  • PCRX $702,772,000.00
  • RYI $4,495,200,000.00
  • Revenue This Year
  • PCRX $7.54
  • RYI $0.35
  • Revenue Next Year
  • PCRX $10.78
  • RYI $3.40
  • P/E Ratio
  • PCRX N/A
  • RYI N/A
  • Revenue Growth
  • PCRX 3.08
  • RYI N/A
  • 52 Week Low
  • PCRX $11.16
  • RYI $17.18
  • 52 Week High
  • PCRX $27.64
  • RYI $27.41
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 37.20
  • RYI 61.26
  • Support Level
  • PCRX $22.82
  • RYI $22.97
  • Resistance Level
  • PCRX $23.83
  • RYI $23.77
  • Average True Range (ATR)
  • PCRX 0.67
  • RYI 0.84
  • MACD
  • PCRX -0.05
  • RYI 0.30
  • Stochastic Oscillator
  • PCRX 20.73
  • RYI 90.17

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority revenue is generated from the United States.

Share on Social Networks: